VIRMA

Across TCGA pan-cancer cohorts, VIRMA mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated VIRMA data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher VIRMA mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated VIRMA expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

HNSC, PDAC, and CCRCC are the cancer types where VIRMA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.900	1.000	.003	28	view →
PDAC	OS	Median	IV	0.491	0.836	.024	3	view →
CCRCC	OS	Quartile	All	0.905	1.000	.031	3	view →
LUAD	OS	Median	III,IV	0.876	0.374	.049	2	view →
GBM	OS	Tertile	All	0.670	0.260	.011	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

VIRMA–HNSC (DFS)

Open the HNSC breakdown →